Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

This multicenter, open‐label phase 1/2 study evaluated single‐agent carfilzomib in 50 heavily pretreated Japanese patients with relapsed/refractory multiple myeloma (median of five prior treatments). In phase 1, patients were dosed at three levels: 15, 20, or 20/27 mg/m(2). Maximum tolerated dosage...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Iida, Shinsuke, Watanabe, Takashi, Matsumoto, Morio, Suzuki, Kenshi, Sunami, Kazutaka, Ishida, Tadao, Ando, Kiyoshi, Chou, Takaaki, Ozaki, Shuji, Taniwaki, Masafumi, Uike, Naokuni, Shibayama, Hirohiko, Hatake, Kiyohiko, Izutsu, Koji, Ishikawa, Takayuki, Shumiya, Yoshihisa, Tobinai, Kensei
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726678/
https://ncbi.nlm.nih.gov/pubmed/31336012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14139
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados